4月30日，据CDE官网消息，北京泰德制药股份有限公司联合申请药品“TCC1727片”，获得临床试验默示许可，受理号CXHL2500225。
公示信息显示，药品“TCC1727片”适应症：本品适用于联合贝莫苏拜单抗注射液、奥拉帕利片或化疗治疗晚期实体瘤。
北京泰德制药股份有限公司，成立于1995年，位于北京市，是一家以从事医药制造业为主的企业。企业注册资本50000万人民币，实缴资本50000万人民币。
通过天眼查大数据分析，北京泰德制药股份有限公司共对外投资了13家企业，参与招投标项目5000次，知识产权方面有商标信息386条，专利信息213条，此外企业还拥有行政许可108个。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.